Arai Y, Toyoshima Y, Kinemuchi H, Tadano T, Kisara K
Neurosci Lett. 1986 Oct 8;70(2):266-71. doi: 10.1016/0304-3940(86)90475-1.
After i.p. injection of 30 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) daily for 4 days and sacrificing the rats 4 h after the last injection, striatal monoamine oxidase (MAO)-A and -B activities, assayed by conventional method with 5-hydroxytryptamine (5-HT) and benzylamine, were not changed. By an uptake technique, with dopamine as the substrate for both uptake and MAO, intrasynaptosomal MAO-A and -B activities were found to be greatly reduced with a greater MAO-A reduction. Intrasynaptosomal 5-HT oxidation by MAO-A was not changed in other forebrain regions treated with these MPTP doses. Similar results were also found with two brain preparations treated with single MPTP doses (30 mg/kg). This reduction in intrasynaptosomal MAO activity was completely absent after treatment with lower MPTP doses (15 mg/kg, daily for 5 days) and 5 days of a withdrawal period. The decrease in MAO activity might have been due to the decrease in DA transport into striatal synaptosomes during the enzyme assay and/or to reversible inhibition of intrasynaptosomal MAO by MPP+.
每天腹腔注射30mg/kg 1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP),持续4天,在最后一次注射后4小时处死大鼠,用5-羟色胺(5-HT)和苄胺通过常规方法检测纹状体单胺氧化酶(MAO)-A和-B活性,结果未发生变化。采用摄取技术,以多巴胺作为摄取和MAO的底物,发现突触体内MAO-A和-B活性显著降低,其中MAO-A降低更为明显。在用这些MPTP剂量处理的其他前脑区域,MAO-A对突触体内5-HT的氧化作用未发生变化。在用单次MPTP剂量(30mg/kg)处理的两种脑标本中也发现了类似结果。在用较低MPTP剂量(15mg/kg,每天5天)处理并经过5天的撤药期后,突触体内MAO活性的这种降低完全不存在。MAO活性的降低可能是由于在酶测定过程中多巴胺向纹状体突触体的转运减少和/或MPP +对突触体内MAO的可逆性抑制所致。